Original Title: Notice Issued by the Municipal Government Office on Several Policy Measures to Promote the High-Quality Development of Wuxi’s Biomedical Industrial Parks To fully implement the spirit of the 14th Provincial and Municipal Party Congresses, thoroughly carry out the core strategy of innovation-driven development and the leading strategy of strengthening the city through industry, promote the high-quality development of the city’s biomedical industrial parks (hereinafter referred to as “the Parks”), further advance the clustering of the biomedical industry, and make every effort to build a flagship biomedical industry, the following policy measures have been formulated.

I. Development Goals

(1) Objectives and Tasks. Enhance the spatial carrying capacity of the industry, establish a “five-in-one” development model comprising leading industries, flagship enterprises, top-tier funds, R&D institutions, and service platforms, and accelerate the transformation and upgrading of the city’s parks toward specialization, distinctiveness, high-end development, and green development. This will ensure a more rational layout of the parks and a significant enhancement of their comprehensive competitiveness, gradually building them into a first-class domestic source of the biopharmaceutical industry, a pioneer zone for innovation and entrepreneurship, and a demonstration zone for coordinated development.By 2025, the city’s industrial parks will have planned 5,000 mu of industrial land, added over 1 million square meters of new research and industrial facilities, established approximately 10 specialized biopharmaceutical industrial parks, and strived to build at least five major innovation platforms; the city’s industrial parks will host more than 2,000 biopharmaceutical enterprises, with an industrial scale exceeding 200 billion yuan.

II. Policy Measures

(2) Optimize the Planning and Layout of Industrial Parks. Coordinate the city-wide industrial development layout, adhere to the strategic planning principle of “one park, one specialty,” and conduct specialized planning and design based on the sub-sectors of the biopharmaceutical industry. Develop industrial development roadmaps and industrial chain investment promotion plans for each park, focusing on creating specialized parks with clear positioning, distinctive characteristics, and comprehensive supporting facilities. Prioritize the planning and construction of city-wide biopharmaceutical manufacturing hubs and high-end manufacturing clusters that meet the required standards.In accordance with the “Notice of the Wuxi Municipal Committee of the Communist Party of China and the Wuxi Municipal People’s Government on Issuing the ‘Implementation Opinions on Accelerating the High-Quality Development of Development Zones to Serve Wuxi’s Efforts to Build a Demonstration Zone for the Practice of New Development Concepts’” (Xiwei Fa [2021] No. 105), support parks in exploring innovative development mechanisms. Through methods such as cooperative construction and equity investment, promote the establishment of “sub-parks,” “supporting parks,” or “production bases.” By exploring mechanisms such as sharing a portion of local tax revenue retained at the local level, we will achieve shared benefits from the construction of circulation projects. (Responsible Units: People’s Governments of all cities [counties] and districts, Wuxi Economic Development Zone Management Committee, Municipal Bureau of Natural Resources and Planning, Municipal Finance Bureau, Municipal Taxation Bureau, Municipal Development and Reform Commission, Municipal Science and Technology Bureau)

(3) Accelerate the development of park infrastructure. Incremental land use quotas and pollutant emission quotas in each district shall be prioritized to support the construction of biopharmaceutical industrial parks, with major industrial projects coordinated at the municipal level. Strengthen professional guidance for the approval of pharmaceutical projects and implement differentiated management from chemical projects. Support the mixed-use of industrial land within parks, pilot new industrial land policies, and prioritize the construction of facilities for other industrial uses and living amenities within biopharmaceutical industrial parks.Conduct comprehensive safety risk assessments, streamline approval procedures for park construction, and promote coordination between environmental impact assessments for park master plans and individual project assessments. Select eligible parks for pilot programs, where projects to be housed in the parks are approved by the park authorities and filed with relevant departments, with the model gradually expanded. Support leading biopharmaceutical enterprises, domestic and international professional institutions, and industrial capital in participating in park construction and operations. Customize specialized facilities to meet the needs of laboratory research, small-batch pilot production, and contract research and manufacturing for pharmaceuticals and medical devices.Support pilot programs for real estate investment trusts (REITs) in infrastructure sectors such as science and technology innovation platforms and standard factory buildings within the parks. (Responsible Units: People’s Governments of all cities [counties] and districts, Wuxi Economic Development Zone Management Committee, Municipal Bureau of Natural Resources and Planning, Municipal Bureau of Ecology and Environment, Municipal Bureau of Emergency Management, Municipal Bureau of Administrative Approval)

(4) Enhance the park’s technological innovation capabilities. Strengthen external cooperation and exchanges, and support the park in collaborating with renowned domestic and international universities, research institutes, scientific teams, leading enterprises, and medical institutions to jointly establish new R&D institutions in cutting-edge life and health technology fields. Where eligible, such initiatives shall be implemented in accordance with the"Policy Opinions on Supporting the High-Quality Development of Modern Industries" (issued as Document No. 59 [2021] of the Wuxi Municipal Party Committee) and the "Several Policy Opinions on Accelerating the Construction of the Wuxi Taihu Bay Science and Technology Innovation Belt" (issued as Document No. 58 [2021] of the Wuxi Municipal Party Committee).Support will be provided to industrial parks striving to establish major innovation platforms such as provincial-level or higher technology innovation centers and clinical medical research centers. Upon certification, tiered rewards of up to 20 million yuan, equivalent to 20% of actual investment, will be granted. Industrial parks are encouraged to increase investment in the construction of public platforms to address the technical needs across the entire process—from R&D to production—of innovative biopharmaceutical products. (Responsible Units: People’s Governments of all cities [counties] and districts, Wuxi Economic Development Zone Administrative Committee, Municipal Science and Technology Bureau, Municipal Finance Bureau, Municipal Health Commission)

(5) Promoting the Aggregation of Competitive Industries. Parks are encouraged to closely follow international industrial development trends, focus on their leading industries and specialized fields, leverage the leading role of flagship enterprises, vigorously introduce major innovation projects, and effectively carry out the work of “filling gaps, strengthening, and extending” industrial chains in niche sectors. This will promote coordinated development across upstream and downstream sectors, “linking chains into clusters,” and enhance their competitiveness and strength.For innovative drugs, improved new drugs, generic drugs, and high-end medical devices that have obtained marketing authorization and are produced and sold in our city, tiered incentives based on sales revenue will be provided for three consecutive years, with a total amount not exceeding 10 million yuan. For marketing authorization holders of drugs and registrants of high-end medical devices who commission local enterprises in our city to manufacture their products or outsource production elsewhere but sell the products within our city, tiered incentives based on sales revenue will be provided for three consecutive years, with a total amount not exceeding 5 million yuan.(Responsible Units: People’s Governments of all cities [counties] and districts, Wuxi Economic Development Zone Management Committee, Municipal Science and Technology Bureau, Municipal Bureau of Industry and Information Technology, Municipal Commerce Bureau, Municipal Finance Bureau)

(6) Attracting High-End Talent Teams. Pilot a talent contribution incentive policy to accelerate the concentration of high-level biopharmaceutical talent in industrial parks. For high-end and scarce biopharmaceutical talent from overseas (including Hong Kong, Macao, and Taiwan) working in Wuxi who have been continuously employed for at least one year, earn an annual salary of 500,000 yuan or more, and pay personal income tax in Wuxi in accordance with the law, a reward of 5% to 20% of their annual salary will be granted, with a maximum annual reward of 2 million yuan per person;The reward program will be implemented through a coordinated effort between the municipal and district levels. Applications will be submitted annually, and the annual list of recipients will be reviewed and approved by the relevant departments. Reward funds will be disbursed in the following year, with the municipal government covering 25% of the total cost. For other high-end and in-demand talent in the biopharmaceutical sector, local districts are encouraged to provide support in accordance with relevant policies. For high-end biopharmaceutical talent (and teams) applying for the “Taihu Talent Program,” requirements such as the upper age limit, length of residence in Wuxi, educational qualifications, and equity ownership ratios will be relaxed.Newly recruited high-level talent will receive a subsidy for the purchase of their first home, and their children will be provided with high-quality public educational resources in their local area. (Responsible Units: Municipal Talent Office, Municipal Finance Bureau, Municipal Science and Technology Bureau, Municipal Human Resources and Social Security Bureau, Municipal Commerce Bureau, Municipal Health Commission, Municipal Taxation Bureau)

(7) Strengthen Industrial Financial Support. Encourage biopharmaceutical industrial parks to establish specialized biopharmaceutical funds to attract more social capital, industrial capital, and financial capital to the biopharmaceutical sector within the parks. In accordance with the “Several Policy Opinions of the Municipal Government on Further Promoting the High-Quality Development of Equity Investment in Wuxi” (Xizhengfa [2021] No. 25), encourage biopharmaceutical equity investment institutions to establish operations in the parks and invest in Wuxi, with eligible institutions receiving a maximum reward of 20 million yuan.Biopharmaceutical funds are encouraged to invest early and in small-scale projects. After completing investments in Wuxi-based early-stage biopharmaceutical enterprises for a full year, a reward of up to 10% of the actual investment amount (limited to monetary contributions) will be granted. The maximum reward subsidy for a single investment project is 1 million yuan, and the maximum annual reward subsidy for each management institution is 5 million yuan.(Responsible Units: Municipal Bureau of Local Financial Supervision, Municipal Science and Technology Bureau, Municipal Finance Bureau, Municipal State-owned Assets Supervision and Administration Commission; People’s Governments of all cities [counties] and districts; Wuxi Economic Development Zone Management Committee)

(8) Enhance the comprehensive service capabilities of industrial parks. Accelerate the establishment of the Wuxi Branch of the Provincial Drug Administration’s Review and Inspection Center, the Wuxi Testing Laboratory of the Provincial Food and Drug Inspection Institute, and the Wuxi Testing Laboratory of the Provincial Medical Device Testing Institute to improve the level of review and approval services for innovative drugs and medical devices. Innovate regulatory services for the entry and exit inspection and quarantine of special items to enhance the customs clearance efficiency of imported and exported biopharmaceutical products. Support comprehensive bonded zones in conducting bonded R&D operations for biopharmaceuticals.Encourage the establishment of full-cycle, one-stop service platforms within the park for GMP management of drug production, medical device approval, and biopharmaceutical intellectual property transactions. Accelerate the application and promotion of products within the park; support joint research and development efforts between medical institutions in Wuxi and enterprises; and ensure that the use of certified innovative drugs, medical devices, and biomaterials produced in Wuxi by medical institutions in the city is excluded from the assessment of the proportion of drugs and consumables in medical institutions.Innovative drugs, newly approved and registered drugs, and marketed products included in the National Special Review Procedure for Innovative Medical Devices may be directly listed for procurement on the Wuxi Pharmaceutical Sunshine Procurement Platform. (Responsible Units: Municipal Market Regulation Bureau, Wuxi Inspection Branch of the Provincial Drug Administration, Wuxi Customs, Municipal Commerce Bureau, Municipal Medical Insurance Bureau, Municipal Health Commission)

III. Support Measures

(9) Strengthen organizational leadership, supervision, and evaluation. Establish a three-tiered working mechanism at the municipal, district, and industrial park levels, with the Municipal Modern Biomedical Industry Promotion Group providing guidance to advance the high-quality development of biomedical industrial parks across the city.Each region shall play a leading role, focusing on major technological innovation and industrialization projects, and providing support in terms of resources and factors of production. Each industrial park shall act as the primary operational entity to ensure the implementation and advancement of all tasks. The Office of the Municipal Modern Biomedical Industry Promotion Group shall strengthen supervision and guidance. Through monitoring and evaluation, it shall promote the development of a number of model biomedical industrial parks and continuously drive the coordinated development of all parks across the city. (Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau, People’s Governments of all Municipal [County] Districts, and Wuxi Economic Development Zone Management Committee)

(10) Strengthen the professional management teams of industrial parks. Optimize mechanisms for personnel appointment, performance evaluation, and compensation incentives in biopharmaceutical industrial parks to stimulate the enthusiasm of park management personnel for innovation and entrepreneurship. Approved parks may implement a salary quota system, determining compensation based on position and performance. Compensation standards for management teams of parks operated by state-owned companies may be set in reference to the standards of state-owned financial institutions in the respective regions.Develop a positive list of responsibilities for park management personnel, deepen the application of error-tolerance and correction mechanisms, and support relevant functional departments in taking proactive measures and daring to innovate in key aspects of industrial development, such as securing policy support, advancing task implementation, optimizing business-friendly services, providing personnel, financial, and material guarantees, and promoting reforms in the construction of the industrial workforce. (Responsible Units: Municipal Party Committee Organization Department, Municipal Party Committee Institutional Reform Office, Municipal Human Resources and Social Security Bureau, Municipal State-owned Assets Supervision and Administration Commission, People’s Governments of all cities [counties] and districts, and Wuxi Economic Development Zone Management Committee)

These policy guidelines apply to biopharmaceutical industrial parks and entities registered in Wuxi City. In cases of overlap or duplication with other industrial support policies, the principles of “the newest, the most favorable, and the highest” shall apply; particularly major projects shall be handled on a case-by-case basis.These policy guidelines shall take effect upon issuance and remain valid until December 31, 2025. They will be adjusted accordingly in the event of major policy changes at the national, provincial, or municipal levels. Jiangyin and Yixing shall formulate corresponding policies based on local conditions.